Table 1.
Baseline characteristics of study participants
| Site | Year | Drug | Enrolled, n | Male, n (%) | Age | Weight in kg mean (range) | Parasitemia geometric mean (range) | |
|---|---|---|---|---|---|---|---|---|
| Mean years (range) | > 15 years, n (%) | |||||||
| Kachin | 2015 | AL | 56 | 37 (66.1) | 34.6 (12–56) | 49 (87.5) | 50.2 (28–65) | 5,794 (744–83,353) |
| Kachin | 2015 | DP | 56 | 41 (73.2) | 38.2 (12–60) | 51 (91.1) | 54 (34–67) | 8,372 (1,188–83,353) |
| Rakhine | 2014 | AL | 70 | 62 (88.6) | 26.6 (18–57) | 70 (100) | 52.6 (25–65) | 10,217 (960–86,520) |
| Rakhine | 2014–15 | DP | 57 | 57 (100) | 27 (12–50) | 54 (94.7) | 54.7 (33–63) | 4,080 (480–104,040) |
| Shan | 2015 | AL | 60 | 43 (71.7) | 35.9 (10–60) | 53 (88.3) | 51.8 (29–61) | 7,392 (550–89,025) |
| Shan | 2015 | DP | 60 | 43 (71.7) | 33.6 (12–58) | 56 (93.3) | 53.3 (30–65) | 7,511 (1,002–98,000) |
AL = artemether–lumefantrine; DP = dihydroartemisinin–piperaquine; n = sample size.